DaVita (DVA)
(Delayed Data from NYSE)
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio
by Zacks Equity Research
Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Best Growth Stocks to Buy for January 5th
by Zacks Equity Research
BROS, DVA and EVBG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 5, 2024.
Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal first quarter benefited from higher branded drug inflation and strong execution in pharmacy services.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout
by Zacks Equity Research
Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.
Bruker (BRKR) Expands Materials Science Research via New Deal
by Zacks Equity Research
Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors continue to remain optimistic about STERIS (STE) due to the prospects of the healthcare business.
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Haemonetics (HAE) Up 11% in a Year: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) owing to its strategic focus on establishing leading positions in high-growth markets and raised guidance.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
Microbot Medical (MBOT) Announces Positive GLP Study Results
by Zacks Equity Research
Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Best Growth Stocks to Buy for January 3rd
by Zacks Equity Research
BROS, DVA and EVBG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 3, 2024.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth, attributable to an aging U.S. population, contract wins, acquisitions and expanding cash reserves.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Bull of the Day: DaVita (DVA)
by Ethan Feller
DaVita has a strong long-term stock performance and multiple bullish catalysts
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
5 Stocks Trading Near 52-Week High That Can Climb Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like DVA, BECN, CASY, FLR and CWCO that are seeing price strength have a high chance of carrying the momentum forward.
Brookdale (BKD) Concludes Transactions to Extend Debt Repayment
by Zacks Equity Research
Brookdale (BKD) completes two financing transactions to push its debt maturities until September 2025, thereby relieving it from the debt repayment burden for next year and focusing on core operations.